Business
Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery
Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery.
About this update from Branded Legacy Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery\r\n \r\n \r\n\r\n\r\nBranded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery\r\nStrategic Acquisition Positions Branded Legacy to Enter the Growing Naloxone and Vaccine Markets, Enhancing Shareholder Value; Leadership Transition Planned with Amin Janmohamed as New CEO and Chairman\r\n\r\n\r\n\r\n\r\n\r\nMELBOURNE, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company focused on innovative health and wellness solutions, today announced the execution of a non-binding Letter of Intent (LOI) to acquire Bio-Legacy Evaluative Group, a pioneering health innovation company specializing in advanced intranasal drug delivery technologies. The LOI, fully executed by both parties, outlines the proposed acquisition of 100% of Bio-Legacy Evaluative Group's equity interests, assets, intellectual property, and operations in exchange for $1.5 million worth of Branded Legacy's Preferred D stock. This strategic move aligns with Branded Legacy's commitment to expanding its portfolio into high-growth sectors addressing global health crises, such as addictions and vaccine accessibility. Bio-Legacy Evaluative Group, led by President & CEO Amin Janmohamed, has assembled a world-class team of experts including Prof. Eran Bendavid, MD (Research Lead, Stanford Professor), Prof. Sonal Singh, MD (Medical Lead, UMass Professor), Prof. Martin Schechter, MD, PhD (Scientific Advisor), and others renowned in addiction medicine, biostatistics, and business development. Bio-Legacy Evaluative Group's patented all-in-one intranasal naloxone delivery device addresses key limitations in the current market, including high costs, inconsistent dosing, and complex systems. By simplifying manufacturing and enhancing dose precision, the technology aims to make naloxone more accessible amid a projected market growth from $371 million in 2022 to over $1.16 billion by 2032, at a CAGR of approximately 11.9%. Additionally, Bio-Legacy Evaluative Group's platform enables nasal administration of compounds previously constrained by physical, chemical, or manufacturing challenges, opening new ...